Michael Baker, MD
Cardiovascular Disease · Nashville, TNNPI 1508839622
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $4,800 of the $4,862 with a category attached, or 98.7%. GE HealthCare accounts for 99.1% of it on its own, with 2 other manufacturers making up the rest. 2025 is the largest year on record at $4,800, more than ten times the $21 reported in 2023.
Across 4 payments — averaging $1215.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GE HealthCare$5K
- Abbott$24
- Amgen$21
Across 74 payments — averaging $6098.41 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abbott$451K
What the payments were for
- Speaking & faculty fees$4,80099%
- Food & beverage$621%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GE HealthCare | 2 | $4,816 |
| Abbott | 1 | $24 |
| Amgen | 1 | $21 |
How this compares
$4,862 in reported general payments places this provider in the 65th percentile of 429 cardiovascular disease providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 331 | $442,719 |
| Repatha SureclickEvolocumab | 111 | $115,360 |
| EntrestoSacubitril/Valsartan | 74 | $100,892 |
| JardianceEmpagliflozin | 54 | $68,787 |
| XareltoRivaroxaban | 56 | $66,241 |
| Praluent PenAlirocumab | 50 | $34,731 |
| FarxigaDapagliflozin Propanediol | 12 | $15,553 |
| Metoprolol Succinate | 338 | $5,006 |
| Ezetimibe | 125 | $3,003 |
| Ranolazine ErRanolazine | 20 | $2,755 |
| Atorvastatin Calcium | 244 | $2,723 |
| Rosuvastatin Calcium | 190 | $2,571 |
| Carvedilol | 160 | $1,538 |
| Flecainide Acetate | 28 | $1,488 |
| Losartan Potassium | 139 | $1,446 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Nashville
- Christopher EllisNashville$527K
- Joann LindenfeldNashville$270K
- Andrew ZurickNashville$231K
- Mark ZenkerNashville$225K
- George CrossleyNashville$197K
- Joel PharesNashville$171K
- Arvindh KanagasundramNashville$161K
- Jessica HustonNashville$109K
- Joshua BeckmanNashville$106K
- Travis RichardsonNashville$87K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.